W
WAVEMAN · COMPANY
YCBD · Cbdmd, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

YCBD

cbdMD, Inc.
PHARMA & BIOTECH · PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS · CIK 0001644903
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
8
13F, latest reported quarter
REVENUE GROWTH
-3.7%
XBRL, annual
NET MARGIN
-10.6%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
8 funds added or opened last quarter
below 89% of Pharma & Biotech
REVENUE
-3.7% year over year
below 63% of Pharma & Biotech
MARGIN
-10.6% net margin
more than 55% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -34.8%
-34.8%12M
-36%+47%+129%+211%2025-092025-102025-122026-032026-052026-072026-09 2025-12-17 · Crosnoe Clark R. sold $1.1M2025-12-17 · Crosnoe Clark R. sold $163.5K2025-12-17 · Crosnoe Clark R. sold $44.7K
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 8 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for cbdMD, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Crosnoe Clark R.
SELL
2025-12-17
69,875.0
$163.5K
Crosnoe Clark R.
SELL
2025-12-17
19,101.0
$44.7K
Crosnoe Clark R.
SELL
2025-12-17
461,725.0
$1.1M
Kennedy Thomas Ronan
Interim CEO and CFO
BUY
2023-05-03
5,000.0
$10.5K
Kennedy Thomas Ronan
CFO & COO
BUY
2021-08-24
7,400.0
$15.1K
6 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Worth Venture Partners, LLC
184,796.0 sh
$124.4K
CSS LLC/IL
137,621.0 sh
$92.6K
VANGUARD CAPITAL MANAGEMENT LLC
119,645.0 sh
$80.5K
CHAPIN DAVIS, INC.
81,250.0 sh
$54.7K
Alesco Advisors, LLC, An ESL Co
68,513.0 sh
$46.1K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
VANGUARD EXTENDED MARKET INDEX FUND
$37.9K POSITION · AS OF 2026-03-31
0.0%
Fidelity Extended Market Index Fund
$1.0K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-092024-092023-092022-09
REVENUE$19.2M$19.9M$25.1M$37.1M
GROSS PROFIT$12.0M$12.0M$15.0M$22.3M
OPERATING INCOME$-2.2M$-3.3M$-22.5M$-78.3M
NET INCOME$-2.0M$-3.7M$-22.9M$-70.1M
EPS (DILUTED)-1.09-14.29-13.32-55.80
OPERATING CASH FLOW$-1.5M$-352.8K$-4.3M$-15.0M
CASH$2.3M$2.5M$1.8M$6.7M
LONG-TERM DEBT$9$125.5K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →